Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Labiana HealthXMAD:LAB 56 Future 3-5Y EPS without NRI Growth Rate is 36.74 as of Jul. 31, 2026. GuruFocus rates XMAD:LAB with a GF Score™ of 56/100 and a GF Value™ of €3.60 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 230 Drug Manufacturers companies, Labiana Health ranks better than 83.48% on this metric.
Future 3-5Y EPS without NRI Growth Rate is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.
As of today, Labiana Health's Future 3-5Y EPS without NRI Growth Rate is 36.74.
Labiana Health (XMAD:LAB) Future 3-5Y EPS without NRI Growth Rate Explanation
Future 3-5Y EPS without NRI Growth Rate s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.
Labiana Health Future 3-5Y EPS without NRI Growth Rate Related Terms
XMAD:LAB vs ZTS, UTHR, VTRS: Future 3-5Y EPS without NRI Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Labiana Health's Future 3-5Y EPS without NRI Growth Rate, along with its competitors' market caps and Future 3-5Y EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Labiana Health Future 3-5Y EPS without NRI Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Labiana Health's Future 3-5Y EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Labiana Health's Future 3-5Y EPS without NRI Growth Rate falls into.
What does a Future 3-5Y EPS without NRI Growth Rate of 36.74 mean?
Labiana Health (XMAD:LAB) has a Future 3-5Y EPS without NRI Growth Rate of 36.74 as of Jul. 31, 2026. EPS Growth Rate (Future 3Y To 5Y Estimate) is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period. View historical data for Labiana Health and its competitors. According to the industry distribution chart, Labiana Health ranks #38 out of 230 companies in the Drug Manufacturers industry, placing it in the top 16.5%.
Is Labiana Health's Future 3-5Y EPS without NRI Growth Rate too high?
Labiana Health's current Future 3-5Y EPS without NRI Growth Rate is 36.74. The Drug Manufacturers industry median Future 3-5Y EPS without NRI Growth Rate is 16.95. Labiana Health's value of 36.74 is 116.8% above this industry median. Based on the distribution chart, Labiana Health ranks #38 out of 230 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Labiana Health has a GF Score™ of 56/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Labiana Health's Future 3-5Y EPS without NRI Growth Rate compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Labiana Health ranks #38 out of 230 companies for Future 3-5Y EPS without NRI Growth Rate. This places Labiana Health in the top 17% of its industry — outperforming the majority of peers. The industry median Future 3-5Y EPS without NRI Growth Rate is 16.95. Labiana Health's value of 36.74 is 116.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Future 3-5Y EPS without NRI Growth Rate for a Drug Manufacturers company?
The median Future 3-5Y EPS without NRI Growth Rate among Drug Manufacturers companies is 16.95, based on 230 companies in the industry. Companies in the top quartile (top 25%) have a Future 3-5Y EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, Future 3-5Y EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Labiana Health's current Future 3-5Y EPS without NRI Growth Rate of 36.74 is 116.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Future 3-5Y EPS without NRI Growth Rate mean?
A high Future 3-5Y EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. EPS Growth Rate (Future 3Y To 5Y Estimate) is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period. View historical data for Labiana Health and its competitors. For the Drug Manufacturers industry, the median Future 3-5Y EPS without NRI Growth Rate is 16.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Labiana Health's current Future 3-5Y EPS without NRI Growth Rate is 36.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Labiana Health stock overvalued right now?
Based on GuruFocus' analysis, Labiana Health (XMAD:LAB) is currently considered Significantly Overvalued. The stock's GF Value™ is €3.60, compared to a current price of €6.35 — trading 76.4% above its estimated fair value. The current Future 3-5Y EPS without NRI Growth Rate is 36.74 and 116.8% above the Drug Manufacturers industry median of 16.95. Labiana Health's overall GF Score™ is 56/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Future 3-5Y EPS without NRI Growth Rate calculated?
Future 3-5Y EPS without NRI Growth Rate is calculated from a company's financial statements. For Labiana Health (XMAD:LAB), the current Future 3-5Y EPS without NRI Growth Rate is 36.74 as of Jul. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Labiana Health (XMAD:LAB) Overvalued in 2026?
Based on GuruFocus' analysis, Labiana Health stock appears to be overvalued.
The current stock price of €6.35 is trading 76.4% above its estimated GF Value™ of €3.60.
GuruFocus considers Labiana Health to be Significantly Overvalued.
Key valuation signals for XMAD:LAB:
Future 3-5Y EPS without NRI Growth Rate: 36.74
GF Value™: €3.60 vs. price of €6.35 (76.4% above fair value)
Industry Position: 116.8% above the Drug Manufacturers median (#38 of 230)
No single metric tells the full story. See the XMAD:LAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Labiana Health SA is a manufacturer of pharmacological products for veterinary use. The company's activities include a GMP manufacturer for EU animal and human health industries, a manufacturer specializing in sterile and lyophilized dosage forms, and a source of development, acquisition, and licensing of molecules such as Fosfomycin Trometamol. The company operates in two segment Animal Health and Human Health.
56GF Score
Get the complete analysis for XMAD:LAB
Future 3-5Y EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XMAD:LAB has been successfully added to your 
